Javier Díez‐Domingo
A5088271216- Respiratory viral infections research
- Influenza Virus Research Studies
- Pneumonia and Respiratory Infections
- Vaccine Coverage and Hesitancy
- Herpesvirus Infections and Treatments
- Bacterial Infections and Vaccines
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
- Hepatitis Viruses Studies and Epidemiology
- Cervical Cancer and HPV Research
- Viral Infections and Immunology Research
- Virology and Viral Diseases
- Hepatitis B Virus Studies
- Acne and Rosacea Treatments and Effects
- Ethics in Clinical Research
- Bartonella species infections research
- COVID-19 epidemiological studies
- Vector-borne infectious diseases
- Tracheal and airway disorders
- Patient Dignity and Privacy
- Poxvirus research and outbreaks
- Patient-Provider Communication in Healthcare
- Genital Health and Disease
- Animal Virus Infections Studies
- COVID-19 Clinical Research Studies
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
2016-2025
Valencia Catholic University Saint Vincent Martyr
2014-2025
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
2006-2025
Instituto de Salud Carlos III
2023-2025
Centro de Investigación Biomédica en Red
2023-2025
Universitat de València
2013-2025
Generalitat Valenciana
2004-2024
Hospital Clínico Universitario de Valladolid
2020
Fundació Clínic per a la Recerca Biomèdica
2020
Universidad Rey Juan Carlos
2020
In previous phase 1-2 clinical trials involving older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant system (called HZ/su) had clinically acceptable safety profile elicited robust immune response.We conducted randomized, placebo-controlled, 3 study in 18 countries to evaluate efficacy of HZ/su adults (≥50 years age), stratified according age group (50 59, 60 69, ≥70 years). Participants received two intramuscular doses or placebo 2 months...
A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and AS01B adjuvant system was associated with a risk 97.2% lower than placebo. second performed concurrently at same sites examined safety efficacy HZ/su in 70 (ZOE-70).This randomized, placebo-controlled, phase 3 conducted 18 countries involved older. Participants received two doses placebo (assigned 1:1 ratio)...
<h3>Context</h3>In the absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a major cause invasive disease in early childhood developed countries.<h3>Objective</h3>To determine immunogenicity and reactogenicity multicomponent MenB vaccine (4CMenB) routine infant vaccines when given either concomitantly or separately.<h3>Design, Setting, Participants</h3>Phase 2b, multicenter, open-label, parallel-group, randomized controlled study 1885 infants enrolled at age 2...
The monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations infants with lower respiratory tract infections (LRTI) positive for syncytial virus (RSV) Spain (Oct 2023–Jan 2024), where a universal immunisation programme began late September (coverage range: 79–99%). High protection confirmed by two methodological designs (screening and test-negative) multicentre active surveillance nine hospitals three regions. No against RSV-negative LRTI-hospitalisations...
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study ZOE-50/70 trials demonstrated that efficacy against herpes remained high. Moreover, safety profile clinically acceptable, suggesting clinical benefit RZV in ≥50-year-olds is sustained up to years.
A 9-valent human papillomavirus (9vHPV) vaccine has been developed to prevent infections and diseases related HPV 6/11/16/18 [as per the licensed quadrivalent (qHPV) vaccine], as well 5 additional oncogenic types (HPV 31/33/45/52/58). Compared with qHPV vaccine, 9vHPV potentially increases coverage of protection from 70% 90% cervical cancers. We compared immunogenicity safety versus in 9-15-year-old girls.Participants (n = 600) were randomized receive or vaccines on day 1, month 2 6....
Abstract Background This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age ≥50 2 pivotal trials (ZOE-50 ZOE-70). The present interim analysis was performed after ≥2 (between 5.1 7.1 [mean] post-vaccination) includes partial data year (Y) 8 post-vaccination. Methods Annual assessments were against herpes (HZ) from Y6 post-vaccination...
We report a rapid increase in enterovirus D68 (EV-D68) infections, with 139 cases reported from eight European countries between 31 July and 14 October 2021. This upsurge is line the seasonality of EV-D68 was presumably stimulated by widespread reopening after COVID-19 lockdown. Most were identified September, but more are to be expected coming months. Reinforcement clinical awareness, diagnostic capacities surveillance urgently needed Europe.
Abstract Respiratory syncytial virus (RSV) infection is a major cause of morbidity in children. However, its disease burden remains poorly understood, particularly outside the hospital setting. Our study aimed to estimate medically attended acute lower respiratory (ALRI) cases potentially related RSV Spanish Longitudinal data from September 2017 June 2018 51,292 children aged < 5 years old National Healthcare System (NHS) two regions were used. Three case definitions considered: (a)...
In May 2020, the ACCESS (The vACCine covid-19 monitoring readinESS) project was launched to prepare real-world of COVID-19 vaccines. Within this project, study aimed generate background incidence rates 41 adverse events special interest (AESI) contextualize potential safety signals detected following administration A dynamic cohort conducted using a distributed data network 10 healthcare databases from 7 European countries (Italy, Spain, Denmark, The Netherlands, Germany, France and United...
Abstract Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infection (ALRI) in children, causing frequent outpatient visits and hospitalizations. Our study aimed to describe the clinical direct economic burden ALRI hospitalizations related RSV children Spain characteristics patients their episodes. In this retrospective study, aged < 5 years for 2015–2018 were reviewed using anonymized administrative public hospital discharge data from Spain. Three case...
Abstract Enterovirus D68 (EV-D68) infections are associated with severe respiratory disease and acute flaccid myelitis (AFM). The European Non-Polio Network (ENPEN) aimed to investigate the epidemiological genetic characteristics of EV-D68 its clinical impact during fall-winter season 2021–2022. From 19 countries, 58 institutes reported 10 481 (6.8%) EV-positive samples which 1004 (9.6%) were identified as (including 852 samples). Clinical data for 969 cases; 78.9% in children (0–5 years);...
Abstract Background Real-World Data (RWD) studies provide important insights in disease epidemiology, real clinical populations, with long follow-up periods. The aim of the present study was to describe epidemiology schizophrenia spectrum disorders (SD) during an 8-year period Spain. Methods A retrospective cohort subjects aged 15 64 years followed-up using electronic healthcare databases Valencia region (2008–2015). SD cases included outpatient and inpatient settings (ICD 9 codes 295.XX)....
In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess possible association and inform policy on future use of adjuvants, we conducted multi-country study adjuvanted pH1N1 vaccines. We used electronic health databases to conduct dynamic retrospective cohort incidence rates (IR) before during virus circulation, after campaigns in Canada, Denmark, Spain, Sweden, Taiwan,...
Abstract Background Estimate the incidence of herpes zoster (HZ), its complications and healthcare utilization rates in adults (≥ 18-years-old) with a wide range immunocompromised (IC) conditions compared to IC-free cohort. Method A population-based retrospective study using Valencia Integrated Databases (VID) (2009–2014). HZ IC were defined ICD-9 codes primary care (PC) hospitalization registers. Incidence (IR), risk HZ, HZ-recurrence, HZ-complications estimated IC-cohort IC-free. Results...